JP2021036915A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021036915A5 JP2021036915A5 JP2020200805A JP2020200805A JP2021036915A5 JP 2021036915 A5 JP2021036915 A5 JP 2021036915A5 JP 2020200805 A JP2020200805 A JP 2020200805A JP 2020200805 A JP2020200805 A JP 2020200805A JP 2021036915 A5 JP2021036915 A5 JP 2021036915A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- aliquot
- domain peptide
- test
- control
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004027 cell Anatomy 0.000 claims 37
- 238000000034 method Methods 0.000 claims 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 238000012360 testing method Methods 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 241001465754 Metazoa Species 0.000 claims 5
- 230000002438 mitochondrial effect Effects 0.000 claims 5
- 239000000443 aerosol Substances 0.000 claims 3
- 239000000975 dye Substances 0.000 claims 3
- 230000005670 electromagnetic radiation Effects 0.000 claims 3
- 230000008823 permeabilization Effects 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 101150082208 DIABLO gene Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000037452 priming Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 231100000167 toxic agent Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- 239000003440 toxic substance Substances 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 102000003829 Adenylate kinase 2 Human genes 0.000 claims 1
- 108090000115 Adenylate kinase 2 Proteins 0.000 claims 1
- 102000007272 Apoptosis Inducing Factor Human genes 0.000 claims 1
- 108010033604 Apoptosis Inducing Factor Proteins 0.000 claims 1
- 102100030497 Cytochrome c Human genes 0.000 claims 1
- 108010075031 Cytochromes c Proteins 0.000 claims 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101100232163 Mus musculus Htra2 gene Proteins 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- PFYWPQMAWCYNGW-UHFFFAOYSA-M [6-(dimethylamino)-9-(2-methoxycarbonylphenyl)xanthen-3-ylidene]-dimethylazanium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.COC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C21 PFYWPQMAWCYNGW-UHFFFAOYSA-M 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000012867 bioactive agent Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 claims 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004020 luminiscence type Methods 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 claims 1
- 210000003470 mitochondria Anatomy 0.000 claims 1
- 231100001143 noxa Toxicity 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 238000003307 slaughter Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153475P | 2015-04-27 | 2015-04-27 | |
| US62/153,475 | 2015-04-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555779A Division JP6814745B2 (ja) | 2015-04-27 | 2016-04-27 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021036915A JP2021036915A (ja) | 2021-03-11 |
| JP2021036915A5 true JP2021036915A5 (enExample) | 2021-11-11 |
Family
ID=57198812
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555780A Active JP6802185B2 (ja) | 2015-04-27 | 2016-04-27 | ハイスループットｂｈ３プロファイリング：少量の細胞でのｂｈ３プロファイルのための迅速かつ拡大縮小可能な技術 |
| JP2017555779A Active JP6814745B2 (ja) | 2015-04-27 | 2016-04-27 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
| JP2020200805A Withdrawn JP2021036915A (ja) | 2015-04-27 | 2020-12-03 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555780A Active JP6802185B2 (ja) | 2015-04-27 | 2016-04-27 | ハイスループットｂｈ３プロファイリング：少量の細胞でのｂｈ３プロファイルのための迅速かつ拡大縮小可能な技術 |
| JP2017555779A Active JP6814745B2 (ja) | 2015-04-27 | 2016-04-27 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10761086B2 (enExample) |
| EP (2) | EP3288964B1 (enExample) |
| JP (3) | JP6802185B2 (enExample) |
| AU (2) | AU2016255749B2 (enExample) |
| CA (1) | CA2983022C (enExample) |
| WO (2) | WO2016176299A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| EP2008106A2 (en) | 2006-03-31 | 2008-12-31 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| CA2885230C (en) | 2012-09-19 | 2021-08-03 | Anthony Letai | Dynamic bh3 profiling |
| JP6663852B2 (ja) | 2013-09-19 | 2020-03-13 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｂｈ３プロファイリングの方法 |
| CA2974240A1 (en) | 2015-01-12 | 2016-07-21 | Eutropics Pharmaceuticals, Inc. | Context dependent diagnostics test for guiding cancer treatment |
| AU2016232833A1 (en) | 2015-03-18 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Selective Mcl-1 binding peptides |
| BR112017022666A8 (pt) | 2015-04-20 | 2022-10-18 | Tolero Pharmaceuticals Inc | Preparando resposta à alvocidib por perfilamento mitocondrial |
| WO2016176299A1 (en) | 2015-04-27 | 2016-11-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
| EP4086264B1 (en) | 2015-05-18 | 2023-10-25 | Sumitomo Pharma Oncology, Inc. | Alvocidib prodrugs having increased bioavailability |
| CA2993659A1 (en) | 2015-08-03 | 2017-02-09 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
| WO2018017922A2 (en) | 2016-07-22 | 2018-01-25 | Massachusetts Institute Of Technology | Selective bfl-1 peptides |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| KR20190099260A (ko) | 2016-12-19 | 2019-08-26 | 톨레로 파마수티컬스, 인크. | 프로파일링 펩티드 및 감도 프로파일링을 위한 방법 |
| JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン |
| US11286299B2 (en) | 2018-09-17 | 2022-03-29 | Massachusetts Institute Of Technology | Peptides selective for Bcl-2 family proteins |
| CA3119807A1 (en) | 2018-12-04 | 2020-06-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| JP7589159B2 (ja) * | 2019-02-26 | 2024-11-25 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| ATE365808T1 (de) | 1995-07-28 | 2007-07-15 | Marie Curie Cancer Care | Transportproteine und deren verwendungen |
| EP0799422A1 (en) * | 1995-10-24 | 1997-10-08 | Sangstat Medical Corporation | Anti alpha-galactosyl screening technique |
| US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| JP2001524301A (ja) | 1997-09-17 | 2001-12-04 | ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ | 新規治療用分子 |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| EP1210098A1 (en) | 1999-04-07 | 2002-06-05 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
| AU6906100A (en) | 1999-08-16 | 2001-03-13 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis |
| WO2002020568A2 (en) | 2000-09-06 | 2002-03-14 | Abbott Laboratories | Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins |
| AU2002258399A1 (en) | 2001-02-16 | 2002-09-19 | Medical College Of Georgia Research Institute, Inc. | Use of trail and antiprogestins for treating cancer |
| AU2002361589A1 (en) | 2001-11-06 | 2003-05-19 | Enanta Pharmaceuticals, Inc. | Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype |
| JP2005518393A (ja) * | 2001-12-21 | 2005-06-23 | アリアス リサーチ、インコーポレイテッド | 個別化抗癌抗体 |
| WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| CA2518555A1 (en) | 2003-03-19 | 2004-09-30 | Alfa Wassermann, Inc. | Separation and accumulation of subcellar components, and proteins derived therefrom |
| WO2005044839A2 (en) | 2003-11-05 | 2005-05-19 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
| WO2006069186A2 (en) | 2004-12-22 | 2006-06-29 | The Ohio State Research Foundation | Small molecule bcl-xl/bcl-2 binding inhibitors |
| JP2005130867A (ja) | 2005-02-16 | 2005-05-26 | Mitokor | ミトコンドリア内カルシウムを使用するスクリーニングアッセイ |
| WO2006099667A1 (en) | 2005-03-21 | 2006-09-28 | The Walter And Eliza Hall Institute Of Medical Research | Prophylactic and therapeutic agents and uses therefor |
| US20070027175A1 (en) | 2005-07-27 | 2007-02-01 | Shaughnessy John Jr | Antineoplastic activities of ellipticine and its derivatives |
| EP2008106A2 (en) | 2006-03-31 | 2008-12-31 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| US8518635B2 (en) | 2006-06-12 | 2013-08-27 | The J. David Gladstone Institutes | Regulation of protein activity by reversible acetylation |
| KR100786759B1 (ko) | 2006-07-07 | 2007-12-18 | 김현기 | Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물 |
| US9360473B2 (en) | 2006-08-16 | 2016-06-07 | Eutropics Pharmaceuticals, Inc. | Assay system to identify therapeutic agents |
| WO2008152405A2 (en) | 2007-06-15 | 2008-12-18 | The Queen's University Of Belfast | Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases |
| EP2200653A2 (en) | 2007-09-10 | 2010-06-30 | University of Massachusetts | Mitochondria-targeted anti-tumour agents |
| WO2009042237A2 (en) | 2007-09-26 | 2009-04-02 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| JP2009240173A (ja) | 2008-03-28 | 2009-10-22 | Univ Of Tokushima | パーキン蛋白の新規糖化因子 |
| CA2767164C (en) | 2009-06-11 | 2019-10-15 | Cynthia Bamdad | Culturing embryonic stem cells, embryonic stem-like cells or induced pluripotent stem cells with a muc1 or muc1* ligand |
| WO2010147961A1 (en) | 2009-06-15 | 2010-12-23 | Precision Therapeutics, Inc. | Methods and markers for predicting responses to chemotherapy |
| US20130122492A1 (en) | 2011-11-14 | 2013-05-16 | Kellbenx Inc. | Detection, isolation and analysis of rare cells in biological fluids |
| CN104541170A (zh) | 2012-05-10 | 2015-04-22 | 尤特罗皮克斯制药股份有限公司 | 对癌症的代理功能性诊断测试 |
| US20150322479A1 (en) * | 2012-06-20 | 2015-11-12 | Cytospan Technologies Corporation | Apparatus and method for quantification of replicative lifespan and observation of senescene |
| CA2885230C (en) | 2012-09-19 | 2021-08-03 | Anthony Letai | Dynamic bh3 profiling |
| JP6327662B2 (ja) | 2012-09-26 | 2018-05-23 | 学校法人藤田学園 | 細胞表面タンパクを抗原とする抗体を測定する方法 |
| JP2016526892A (ja) | 2013-07-18 | 2016-09-08 | ユートロピクス ファーマシューティカルズ， インコーポレイテッド | 示差的ｂｈ３ミトコンドリアプロファイリング |
| JP6663852B2 (ja) | 2013-09-19 | 2020-03-13 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｂｈ３プロファイリングの方法 |
| WO2016176299A1 (en) | 2015-04-27 | 2016-11-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
| US11092602B2 (en) | 2015-07-06 | 2021-08-17 | Whitehead Institute For Biomedical Research | Methods and compositions relating to proteasome inhibitor resistance |
| JP7589159B2 (ja) | 2019-02-26 | 2024-11-25 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング |
-
2016
- 2016-04-27 WO PCT/US2016/029510 patent/WO2016176299A1/en not_active Ceased
- 2016-04-27 AU AU2016255749A patent/AU2016255749B2/en active Active
- 2016-04-27 JP JP2017555780A patent/JP6802185B2/ja active Active
- 2016-04-27 US US15/568,994 patent/US10761086B2/en active Active
- 2016-04-27 AU AU2016253957A patent/AU2016253957C1/en active Active
- 2016-04-27 CA CA2983022A patent/CA2983022C/en active Active
- 2016-04-27 US US15/569,851 patent/US20180120297A1/en not_active Abandoned
- 2016-04-27 JP JP2017555779A patent/JP6814745B2/ja active Active
- 2016-04-27 EP EP16787039.3A patent/EP3288964B1/en active Active
- 2016-04-27 WO PCT/US2016/029495 patent/WO2016176288A1/en not_active Ceased
- 2016-04-27 EP EP16787045.0A patent/EP3289094B1/en active Active
-
2020
- 2020-07-27 US US16/939,736 patent/US11867688B2/en active Active
- 2020-12-03 JP JP2020200805A patent/JP2021036915A/ja not_active Withdrawn
-
2021
- 2021-02-26 US US17/186,344 patent/US20210255167A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021036915A5 (enExample) | ||
| JP2018520638A5 (enExample) | ||
| Mao et al. | Folding of the mitochondrial proton adenosine triphosphatase proteolipid channel in phospholipid vesicles | |
| Yamamoto et al. | Analysis of the structure and function of EMRE in a yeast expression system | |
| Korner et al. | Solubility of albumin in alcohol after precipitation by trichloroacetic acid: a simplified procedure for separation of albumin | |
| Zingsheim et al. | Electron microscopic methods in membrane biology | |
| JP2020012850A (ja) | Ｂｈ３プロファイリングの方法 | |
| JP2021036915A (ja) | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 | |
| Asghar et al. | Histochemical localization of glutathione in tissues. | |
| Bismuto et al. | Unfolding pathway of myoglobin. Evidence for a multistate process | |
| Murata et al. | Membrane fusion activity of succinylated melittin is triggered by protonation of its carboxyl groups | |
| JP3127996B2 (ja) | 合成老化細胞抗原 | |
| CN108267579A (zh) | 稳定保存稀释液、抗核抗体检测试剂及其制备方法和应用 | |
| Nakamura et al. | Derivatization of compounds at the origin of thin-layer plates with fluorescamine | |
| CN107703109B (zh) | 二维硫化钼多肽复合材料及其在靶向cd47癌症标记中的应用 | |
| Ghang et al. | Anionic deep cavitands enable the adhesion of unmodified proteins at a membrane bilayer | |
| CN112816684B (zh) | 血清淀粉样蛋白a的校准品稀释液、其制备方法及其应用 | |
| CA2259413A1 (en) | Methods for determining the presence of brain protein s-100 | |
| CN108609617B (zh) | 一种多肽改性的石墨烯量子点gsg及其制备方法与制备赖氨酸荧光检测试剂上的应用 | |
| Schlesinger | [63] Fatty acid acylation of eukaryotic cell proteins | |
| Azmi et al. | Introduction of cell‐selectivity in bovine cathelicidin BMAP‐28 by exchanging heptadic isoleucine with the adjacent proline at a non‐heptadic position | |
| Say et al. | Investigation of photosensitively bioconjugated targeted quantum dots for the labeling of Cu/Zn superoxide dismutase in fixed cells and tissue sections | |
| Poccia et al. | Fluorescence staining of living cells with fluorescamine | |
| Kordyukova et al. | Mass spectrometric approaches to study enveloped viruses: new possibilities for structural biology and prophylactic medicine | |
| Causey et al. | Detection of low affinity interactions between peptides and heat shock proteins by chemiluminescence of enhanced avidity reactions (CLEAR) |